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Amyloidosis is caused by dysregulation of protein folding resulting in systemic or organ spe-
cific amyloid aggregation. When affecting the heart, amyloidosis can cause severe heart fail-
ure, which is associated with a high morbidity and mortality. Different subtypes of cardiac
amyloidosis exist e.g. transthyretin cardiac amyloidosis and senile cardiac amyloidosis.
Today, diagnostics is primarily based on cardiac biopsies and no clinically used circulating
blood-based biomarkers existing. Therefore, our aim was to identify circulating microRNAs
in patients with different forms of amyloidosis.
Methods
Blood was collected from healthy subjects (n = 10), patients with reduced ejection fraction
(EF < 35%; n = 10), patients affected by transthyretin cardiac amyloidosis (n = 13) as well as
senile cardiac amyloidosis (n = 11). After performing TaqMan array profiling, promising can-
didates, in particular miR-99a-5p, miR-122-5p, miR-27a-3p, miR-221-3p, miR-1180-3p,
miR-155-5p, miR-339-3p, miR-574-3p, miR-342-3p and miR-329-3p were validated via
quantitative real time PCR.
Results
The validation experiments revealed a significant upregulation of miR-339-3p in patients
affected with senile cardiac amyloidosis compared to controls. This corresponded to the
array profiling results. In contrast, there was no deregulation in the other patient groups.
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Conclusion
MiR-339-3p was increased in blood of patients with senile cardiac amyloidosis. Therefore,
miR-339-3p is a potential candidate as biomarker for senile cardiac amyloidosis in future
studies. Larger patient cohorts should be investigated.
Introduction
Amyloidosis is a rare and very heterogeneous disease, which can affect several human organs.
Pathophysiological amyloidosis is caused by misfolding of non-soluble proteins, which deposit
in an extracellular manner. When affecting the heart, cardiac amyloidosis can lead to to car-
diac hypertrophy [1,2]. The most common type in the cardiac form is induced by light chain
immunoglobulins (AL amyloidosis). In general, the AL type manifests systemically affecting
also e.g. the liver or kidney. Another form of this disease is the transthyretin type amyloidosis
also called ATTR amyloidosis. A different type affecting mainly men older than 70 years is the
wild-type ATTR amyloidosis also named senile cardiac amyloidosis (SCA) [3]. For diagnosis
of amyloidosis, cardiac biopsy and echocardiography are used. Until now, there is not any spe-
cific biomarker in blood known [3,4].
MicroRNAs (miR’s, miRNAs) are small ribonucleic acids about 20 nucleotides. As impor-
tant regulators they orchestrate post-transcriptionally gene-expression and are therefore
involved in cell differentiation processes [5]. In cardiac diseases they are important players in
pathologic processes like e.g. cardiac fibrosis and hypertrophy [6]. Therefore, microRNAs can
be used as therapeutic targets. More and above, microRNAs circulating in the blood are used
as biomarkers for example in Takotsubo syndrome or Hypertrophic cardiomyopathy [7,8].
The aim of our study was to find specific blood-based microRNAs in serum of patients with
different forms of cardiac amyloidosis.
Materials and methods
Study population
All patients including control and heart failure individuals were recruited at the Columbia
University Medical Center in New York. All patients gave written informed consent to partici-
pate in the study, which was conducted in accordance with the protocol approved by the Insti-
tutional Review Board at Columbia University Medical Center. The diagnosis of different
types of amyloidosis was defined by myocardial biopsy and echocardiography. In the heart fail-
ure group (HF) only patients with an ejection fraction (EF) < 35% and without amyloidosis or
other genetic diseases were included.
RNA isolation from patient blood samples
To obtain liquid supernatant by separating the corpuscular components, the serum samples
were centrifuged for 10 minutes at 2000 x g at room temperature. Afterwards the supernatant
was stored at -80˚C. The miRNeasy Mini Kit (Qiagen) was utilized according to instructions
for the RNA isolation. For subsequent normalization synthetic Caenorhabditis elegans miR-39
(5 μl of 1 fmol/μl) was added as spike-in control during RNA isolation to the Qiazol/chloro-
form/plasma mixture [8].
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TaqMan ArrayCard microRNA screening
For performing a microRNA expression profile isolated RNA of single individuals were pooled
within their groups. After preamplification, TaqMan gene expression array cards– 384-well
microfluidic cards (ThermoFisher SCIENTIFIC) were used according to manufacturer’s
instructions. 753 different reactions of microRNA were measured. For analyzing array data we
used -ddCT method.
Validation of microRNA candidates using realtime PCR
TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems) was used according to
developer’s instructions to transcribe the isolated RNA of each blood sample to their comple-
mentary DNA (cDNA). For validation the microRNAs miR-99a-5p, miR-122-5p, miR-27a-3p,
miR-221-3p, miR-1180-3p, miR-155-5p, miR-339-3p, miR-574-3p, miR-342-3p and miR-329-
3p were chosen. By using TaqMan MicroRNA assays (Applied Biosystems) the microRNAs
were amplified with quantitative realtime PCR (qrt-PCR). Afterwards expression results were
normalized to cel-miR-39. qPCR was performed on a Viia7 Real-Time PCR system (Thermo
Fisher Scientific) (15 min at 95˚C, 45 cycles of 15 sec at 95˚C and 1 min at 60˚C). The Quant-
StudioTM Real-Time PCR software (v1.1) was used to determine quantification cycle. Ct was
defined as the fractional cycle number at which the fluorescence exceeded a given threshold.
Relative quantification was performed using the 2-dCt method, where dCt = Ct[miRNA]—Ct
[cel-miR-39].
Statistical analysis
For statistical analysis and graphical illustration of demographics and expression data Graph
Pad Prism 6 was utilized. For analyzing the regulation of miRNAs between the different
Table 1. Patient groups.
Control HF TTR SCA
number 10 10 13 11
age [y] ± SD 62.70 ± 6.45 70.50 ± 6.08 67.54 ± 8.31 78.45 ± 4.57
gender f = 3; m = 7 f = 0; m = 10 f = 4; m = 9 f = 0; m = 11
HF = heart failure; TTR = transthyretin; SCA = senile cardiac amyloidosis; y = years; SD = standard deviation; f = female; m = male
https://doi.org/10.1371/journal.pone.0204235.t001
Table 2. Demographics.
HF TTR SCA HF vs. TTR vs. SCA
BMI [kg/sq m) ± SD 26.18 ± 2.46 27.42 ± 5.20 25.24 ± 4.13 ns
Diabetes mellitus [%] 50.00% (n = 5) 15.38% (n = 2) 27.27% (n = 2) ns
LVEF [%] ± SD 26.00 ± 5.35 36.25 ± 16.67 41.18 ± 15.14 ns
BNP [pg/ml] ± SD 341.4 ± 336.9 775.3 ± 821.6 818.4 ± 862.0 ns
Hct [%] ± SD 39.59 ± 4.17 40.18 ± 5.01 39.27 ± 6.90 ns
HDL [mg/dl] ± SD 37.33 ± 8.31 45.33 ± 16.67 51.33 ± 13.94 ns
LDL [mg/dl] ± SD 73.22 ± 24.19 81.89 ± 41.75 82.17 ± 43.61 ns
HF = heart failure; TTR = transthyretin; SCA = senile cardiac amyloidosis; BMI = body mass index; LVEF = left ventricular ejection fraction; BNP = Brain natriuretic
peptide; Hct = Haematocrit; ns = not significant; H/LDL = High/Low Density Protein
https://doi.org/10.1371/journal.pone.0204235.t002
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patient groups and control based on Ct-values Kruskal-Wallis test (Nonparametric One-way
ANOVA multi comparison test) were used. Graphs were illustrated as scatter plots with stan-




In this study, 10 controls, 10 heart failure patients, 13 TTR mutation patients and 11 senile car-
diac amyloidosis patients were included. There were no statistical significant differences in age
of controls, heart failure and TTR group but the patients affected with senile cardiac amyloid-
osis were significantly older than control and TTR group. Comparing the gender, in all groups
more men than women were included (Table 1). There was no difference in BMI. In the heart
failure group we included more patients with diabetes mellitus but this was without statistical
significance. Comparing cholesterol, in particular LDL and HDL cholesterol, there was also no
difference (Table 2).
Fig 1. Volcano plot comparing SCA to control. X-axis = -log2 of Fold Change (FC), Y-axis = p-value; SCA = senile cardiac amyloidosis. SCA " = SCA upregulation.
https://doi.org/10.1371/journal.pone.0204235.g001
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MicroRNA-Array results
Comparing the control group to SCA patients, miR-329-3p, miR-342-3p, miR-339-3p and
miR-99a-5p were significantly upregulated in SCA. In contrast, miR-27a-3p and miR-221-3p
were decreased (Fig 1). When comparing the heart failure group with SCA group there was a
significant upregulation of miR-574-3p, miR-501-5p, miR-99a-5p, miR-1227-3p, miR-151-3p,
miR-1180-3p and miR-155-5p. Similar to the control group miR-122-5p was decreased as well
as miR-27a-3p (Fig 2). Nevertheless, while comparing TTR group and SCA patients the miR-
NAs miR-342-3p, miR-574-3p, miR-99a-5p, miR-664-3p, miR-1180-3p, miR-1271-5p, miR-
329-3p and miR-339-3p were significantly increased in SCA group. Whereas, miR-122-5p and
miR-133a-3p were downregulated (Fig 3). Based on these results the microRNAs miR-99a-5p,
miR-122-5p, miR-27a-3p, miR-221-3p, miR-1180-3p, miR-155-5p, miR-339-3p, miR-574-3p,
miR-342-3p and miR-329-3p were chosen for validation.
Validation data
Looking at the validated microRNA selection, there was no dysregulation of the circulating
miR-99a-5p and miR-122-5p between the different groups (Fig 4A and 4B). Beside it, the
Fig 2. Volcano plot comparing SCA to HF. X-axis = -log2 of Fold Change (FC), Y-axis = p-value; SCA = senile cardiac amyloidosis; HF = heart failure. SCA " = SCA
upregulation.
https://doi.org/10.1371/journal.pone.0204235.g002
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circulating expression of miR-27a was not increased in any group, but significantly decreased
in TTR patients compared to control (Fig 4C). There were also no differences in circulating
levels of the microRNAs miR-221-3p, miR-1180-3p, miR-155-5p and miR-342-3p (Fig 4D, 4E,
4F and 4G). In addition, levels of miR-339-3p were significantly increased in patients with
senile cardiac amyloidosis whereas not in the other patient groups (Fig 5). Primer sequences of
validated microRNAs are shown in Table 3.
Discussion
In this study, we performed a microRNA assay in samples derived from patients with different
forms of cardiac amyloidosis and validated promising biomarker candidates to distinguish dif-
ferent forms of amyloidosis, heart failure patients as well as healthy individuals. Up to date,
there is no other study showing the regulation of microRNAs in cardiac amyloidosis. In array
profiling experiments, we found 10 candidates being deregulated in TTR amyloidosis and
senile cardiac amyloidosis.
Fig 3. Volcano plot comparing SCA to TTR. X-axis = -log2 of Fold Change (FC), Y-axis = p-value; SCA = senile cardiac amyloidosis; TTR = transthyretin. SCA " =
SCA upregulation.
https://doi.org/10.1371/journal.pone.0204235.g003
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MicroRNA miR-99a, which was upregulated in array profiling in patients with SCA, was
recently shown as tumor suppressor in lung cancer working together with oncogenic proteins
EMR2 and E2F2 [9]. In validation experiments, this miRNA failed as possible biomarker for
cardiac amyloidosis. Also, miR-574-3p and miR-329 was detected only in a very low number
of patient samples. Moreover, miR-122, which was previously described as marker of neuro-
logical damage in blood of patients after cardiac arrest [10], did not show any significant regu-
lation in patients with cardiac amyloidosis. Further, miR-155 also failed in our validation
cohort as potential biomarker for cardiac amyloidosis. In heart diseases, miR-155 is described
as a promoter of cardiac hypertrophy leading to heart failure [11]. Interestingly, we found that
Fig 4. Validation. microRNA expression in controls, heart failure (HF) patients, transthyretin (TTR) group and senile
cardiac amyloidosis (SCA). ns = not significant.
https://doi.org/10.1371/journal.pone.0204235.g004
Fig 5. Validation. microRNA miR-339-3p expression in controls, heart failure (HF) patients, transthyretin (TTR) group and senile cardiac amyloidosis
(SCA).
https://doi.org/10.1371/journal.pone.0204235.g005
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miR-339-3p was significantly upregulated in both array data and validation analysis compared
to control samples. Until today, miR-339-3p has not been described as a specific circulating
biomarker in any heart disease. There is also no previously reported association between miR-
339-3p and amyloidosis. It is known that miR-339-3p functions as a suppressor in melanoma
by targeting the oncogene MCL1 [12]. Besides melanoma, miR-339-3p is also described as
inhibitor for colorectal cancer tumor growth in in-vitro experiments [13]. Thus, miR-339-3p
was mainly known in the cancer field. However, our work suggests that miR-339-3p will be a
promising candidate as clinical biomarker for senile cardiac amyloidosis. The exact pathophys-
iological mechanisms of the origin and secretion of miR-339-3p into the blood in cardiac amy-
loidosis remains unclear and needs to be explored in future studies. Although, miR-221 was
described as promoter of cardiac hypertrophy [14], it was not dysregulated in our validation
experiments. Also expression levels of miR-27a described e.g. as anti-hypertrophic in rat cardi-
omyocytes [15] and miR-1180-3p were not significantly dysregulated in any of our patient
groups. Interestingly, miR-342-3p being described as decreased in acute heart failure did not
show any dysregulation either in our heart failure group or in cardiac amyloidosis groups
[16,17].
In this study are also limitations. The unbalanced age of the senile cardiac amyloidosis
group is most likely due to the incidence of the disease in higher ages. Another limitation is
the small sample size within the different groups owing to the relative rareness of cardiac amy-
loidosis and therefore the small patient population. In addition, our study did not reveal the
pathomechanism behind the upregulation of miR-339-3p in patients with senile cardiac
amyloidosis.
Conclusion
In conclusion, miR-339-3p was increased in the plasma of patients with senile cardiac amy-
loidosis as identified by array profiling and validated by qPCR. Thus, miR-339-3p is a potential
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